Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Pharmaceutical giant Moderna, Inc. (NASDAQ:MRNA) saw its share prices drop by 9.39 percent on Wednesday to close at $40.72 ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (BRSE:0QF) from Buy to Neutral. There are 1,448 funds or institutions reporting positions in Moderna.

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months. Moderna shares MRNA fell 2% in ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

Shares of vaccine maker Moderna Inc. fell Wednesday as Goldman Sachs lowered its rating after the biotech's second cut to product revenue guidance in six months. Moderna shares (MRNA) fell 2% in ...